Aktis Oncology (NASDAQ:AKTS) Receives Consensus Rating of “Moderate Buy” from Brokerages

Shares of Aktis Oncology (NASDAQ:AKTS) have been given an average recommendation of “Moderate Buy” by the eight research firms that are presently covering the firm, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, six have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12 month price objective among brokers that have issued ratings on the stock in the last year is $34.60.

AKTS has been the topic of a number of research analyst reports. HC Wainwright increased their price objective on shares of Aktis Oncology from $33.00 to $35.00 and gave the company a “buy” rating in a research note on Tuesday, June 2nd. Wall Street Zen lowered Aktis Oncology from a “hold” rating to a “sell” rating in a report on Saturday, July 25th. Raymond James Financial began coverage on Aktis Oncology in a research report on Monday, June 15th. They issued a “strong-buy” rating and a $40.00 target price for the company. William Blair assumed coverage on Aktis Oncology in a research note on Wednesday, April 29th. They set an “outperform” rating on the stock. Finally, Weiss Ratings raised shares of Aktis Oncology from a “sell (d)” rating to a “sell (d+)” rating in a report on Tuesday, June 23rd.

Insider Activity

In related news, Director Ken Herrmann sold 4,856 shares of the business’s stock in a transaction that occurred on Monday, July 20th. The stock was sold at an average price of $24.56, for a total transaction of $119,263.36. Following the completion of the transaction, the director owned 3,506 shares in the company, valued at $86,107.36. The trade was a 58.07% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Company insiders own 3.30% of the company’s stock.

Aktis Oncology Stock Performance

Shares of NASDAQ:AKTS opened at $22.65 on Thursday. Aktis Oncology has a 1 year low of $14.72 and a 1 year high of $34.19. The stock has a 50-day simple moving average of $24.39 and a 200-day simple moving average of $20.98. The stock has a market capitalization of $1.21 billion and a P/E ratio of -59.61.

Aktis Oncology (NASDAQ:AKTS) last announced its earnings results on Monday, May 11th. The technology company reported ($0.38) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.37) by ($0.01). The business had revenue of $3.23 million during the quarter, compared to the consensus estimate of $2.23 million. Analysts predict that Aktis Oncology will post -1.64 earnings per share for the current year.

About Aktis Oncology

Aktis Oncology (NASDAQ: AKTS) is a biotechnology company focused on the discovery and development of new therapies for cancer. The firm concentrates on advancing oncology candidates through research and development with the goal of addressing unmet medical needs in oncology. Its work emphasizes targeted and precision approaches intended to improve the safety and efficacy profiles of cancer treatments.

The company’s activities include laboratory research, preclinical studies and clinical development as it advances its pipeline programs toward regulatory milestones.